机构

• 上海药物研究所 [12]

采集方式

• OAI收割 [12]

内容类型

• 期刊论文 [12]

发表日期

• 2024 [1]
• 2023 [2]
• 2022 [2]
• 2021 [1]
• 2020 [1]
• 2017 [4]
• 更多

学科主题

筛选

浏览/检索结果: 共12条，第1-10条 帮助 限定条件 专题：上海药物研究所    第一署名单位    第一作者单位    通讯作者单位     条数/页： 5101520253035404550556065707580859095100 排序方式： 请选择提交时间升序提交时间降序发表日期升序发表日期降序题名升序题名降序作者升序作者降序 Proteomics analysis of histone deacetylase inhibitor-resistant solid tumors reveals resistant signatures and potential drug combinations 期刊论文  OAI收割 ACTA PHARMACOLOGICA SINICA, 2024, 页码: 11 作者:  Hao, Bing-bing;  Ma, Ke;  Xu, Jun-yu;  Fan, Ru-feng;  Zhao, Wen-si   |  收藏  |  浏览/下载：13/0  |  提交时间：2024/03/25 solid tumor  histone deacetylase inhibitor  vorinostat (SAHA)  drug resistance  proteomics   Epigenetic-based combination therapy and liposomal codelivery overcomes osimertinib-resistant NSCLC via repolarizing tumor-associated macrophages 期刊论文  OAI收割 ACTA PHARMACOLOGICA SINICA, 2023, 页码: 12 作者:  Lin, Ting-ting;  Xiong, Wei;  Chen, Gui-hua;  He, Yang;  Long, Li   |  收藏  |  浏览/下载：6/0  |  提交时间：2024/01/26 osimertinib resistance  targeted drug delivery  liposomes  panobinostat  tumor-associated macrophage  combination therapy   TI17, a novel compound, exerts anti-MM activity by impairing Trip13 function of DSBs repair and enhancing DNA damage 期刊论文  OAI收割 CANCER MEDICINE, 2023, 页码: 14 作者:  Chang, Shuaikang;  Xiao, Wenqin;  Xie, Yongsheng;  Xu, Zhijian;  Li, Bo   |  收藏  |  浏览/下载：7/0  |  提交时间：2023/12/11 DNA damage  DSBs repair  myeloma  TI17  Trip13   The HDAC inhibitor GCJ-490A suppresses c-Met expression through IKK? and overcomes gefitinib resistance in non-small cell lung cancer 期刊论文  OAI收割 CANCER BIOLOGY & MEDICINE, 2022, 卷号: 19, 期号: 8, 页码: 1172-1192 作者:  He, Ting;  Gao, Yinglei;  Fang, Yanfen;  Zhang, Yangming;  Zhang, Shuwei   |  收藏  |  浏览/下载：9/0  |  提交时间：2024/03/21 HDAC inhibitor  c-Met  IKK?  NSCLC  gefitinib   Remodeling "cold" tumor immune microenvironment via epigenetic-based therapy using targeted liposomes with in situ formed albumin corona 期刊论文  OAI收割 ACTA PHARMACEUTICA SINICA B, 2022, 卷号: 12, 期号: 4, 页码: 2057-2073 作者:  He, Yang;  Fang, Yuefei;  Zhang, Meng;  Zhao, Yuge;  Tu, Bin   |  收藏  |  浏览/下载：18/0  |  提交时间：2022/08/16 Tumor immune microenvironment  Tumor-associated macrophage  Epigenetic therapy  Immune checkpoint  Angiogenesis  Panobinostat  JQ1  Liposome   Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma 期刊论文  OAI收割 ACTA PHARMACOLOGICA SINICA, 2021, 页码: 9 作者:  Zhou, Yu-bo;  Zhang, Yang-ming   |  收藏  |  浏览/下载：67/0  |  提交时间：2021/11/04 multiple myeloma  HDAC inhibitor  bisthianostat  pharmacodynamics  pharmacokinetics  phase 1a clinical trial  antitumor drug   A Small-Molecule Inhibitor Targeting TRIP13 Suppresses Multiple Myeloma Progression 期刊论文  OAI收割 CANCER RESEARCH, 2020, 卷号: 80, 期号: 3, 页码: 536-548 作者:  Wang, Yingcong;  Huang, Jing;  Li, Bo;  Xue, Han;  Tricot, Guido   |  收藏  |  浏览/下载：42/0  |  提交时间：2020/07/01 DCZ3301, a novel cytotoxic agent, inhibits proliferation in diffuse large B-cell lymphoma via the STAT3 pathway 期刊论文  OAI收割 CELL DEATH & DISEASE, 2017, 卷号: 8 作者:  Sun, Xi;  Li, Bo;  Xie, Bingqian;  Xu, Zhijian;  Chang, Gaomei   |  收藏  |  浏览/下载：61/0  |  提交时间：2019/01/08 The blueberry component pterostilbene has potent anti-myeloma activity in bortezomib-resistant cells 期刊论文  OAI收割 ONCOLOGY REPORTS, 2017, 卷号: 38, 期号: 1, 页码: 488-496 作者:  Chen, Gege;  Xu, Zhijian;  Chang, Gaomei;  Hou, Jun;  Hu, Liangning   |  收藏  |  浏览/下载：24/0  |  提交时间：2019/01/08 pterostilbene  multiple myeloma  bortezomib-resistant cells  apoptosis  cell cycle  histone deacetylase inhibitors   Dihydrocelastrol inhibits multiple myeloma cell proliferation and promotes apoptosis through ERK1/2 and IL-6/STAT3 pathways in vitro and in vivo 期刊论文  OAI收割 ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2017, 卷号: 49, 期号: 5, 页码: 420-427 作者:  Hu, Liangning;  Wu, Huiqun;  Li, Bo;  Song, Dongliang;  Yang, Guang   |  收藏  |  浏览/下载：26/0  |  提交时间：2019/01/08 dihydrocelastrol  multiple myeloma  apoptosis